Literature DB >> 16439540

Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif.

Scott H Coleman1, Ricardo Madrid, Nanette Van Damme, Richard S Mitchell, Jerome Bouchet, Cecile Servant, Satish Pillai, Serge Benichou, John C Guatelli.   

Abstract

The nef gene contributes to the replication of primate lentiviruses by altering the trafficking of cellular proteins involved in adaptive immunity (class I and II major histocompatibility complex [MHC]) and viral transmission (CD4 and DC-SIGN). A conserved acidic leucine-based sequence (E(160)xxxLL) within human immunodeficiency virus type 1 (HIV-1) Nef binds to the cellular adaptor protein (AP) complexes, which mediate protein sorting into endosomal vesicles. The leucine residues in this motif are required for the down-regulation of CD4 and for the up-regulation of DC-SIGN and the invariant chain of MHC class II, but the role of the acidic residue is unclear. Here, substitution of E160 with uncharged residues impaired the ability of Nef to up-regulate the expression of the invariant chain and DC-SIGN at the cell surface, whereas substitution with a basic residue was required for a similar effect on the down-regulation of CD4. All substitutions of E160 relieved the Nef-mediated block to transferrin uptake. E160 was required for the efficient interaction of Nef with AP-1 and AP-3 and for the stabilization of these complexes on endosomal membranes in living cells. Systematic mutation of the ExxxLL sequence together with correlation of binding and functional data leads to the hypotheses that AP-1 and AP-3 are major cofactors for the effect of Nef on the trafficking of transferrin, are less important but contribute to the modulation of the invariant chain and DC-SIGN, and are least critical for the modulation of CD4. The data suggest that the E160 residue plays a differential role in the modulation of leucine-dependent Nef-targets and support a model in which distinct AP complexes are used by Nef to modulate different cellular proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439540      PMCID: PMC1367136          DOI: 10.1128/JVI.80.4.1837-1849.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Mechanism for down-regulation of CD28 by Nef.

Authors:  T Swigut; N Shohdy; J Skowronski
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

2.  HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread.

Authors:  Nathalie Sol-Foulon; Arnaud Moris; Cinzia Nobile; Claire Boccaccio; Anneke Engering; Jean-Pierre Abastado; Jean-Michel Heard; Yvette van Kooyk; Olivier Schwartz
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

3.  HIV-1 Nef impairs MHC class II antigen presentation and surface expression.

Authors:  P Stumptner-Cuvelette; S Morchoisne; M Dugast; S Le Gall; G Raposo; O Schwartz; P Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

4.  HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway.

Authors:  Anastassia D Blagoveshchenskaya; Laurel Thomas; Sylvain F Feliciangeli; Chien Hui Hung; Gary Thomas
Journal:  Cell       Date:  2002-12-13       Impact factor: 41.582

5.  The di-leucine motif in the cytoplasmic tail of CD4 is not required for binding to human immunodeficiency virus type 1 Nef, but is critical for CD4 down-modulation.

Authors:  Matthew Bentham; Sabine Mazaleyrat; Mark Harris
Journal:  J Gen Virol       Date:  2003-10       Impact factor: 3.891

Review 6.  Clathrin and adaptors.

Authors:  J Hirst; M S Robinson
Journal:  Biochim Biophys Acta       Date:  1998-08-14

7.  HIV-1 Nef stabilizes the association of adaptor protein complexes with membranes.

Authors:  Katy Janvier; Heather Craig; Douglas Hitchin; Ricardo Madrid; Nathalie Sol-Foulon; Louis Renault; Jacqueline Cherfils; Dan Cassel; Serge Benichou; John Guatelli
Journal:  J Biol Chem       Date:  2002-12-16       Impact factor: 5.157

8.  Two independent regions of HIV-1 Nef are required for connection with the endocytic pathway through binding to the mu 1 chain of AP1 complex.

Authors:  L Erdtmann; K Janvier; G Raposo; H M Craig; P Benaroch; C Berlioz-Torrent; J C Guatelli; R Benarous; S Benichou
Journal:  Traffic       Date:  2000-11       Impact factor: 6.215

9.  Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors.

Authors:  Minoru Tobiume; Mikako Takahoko; Takeshi Yamada; Masashi Tatsumi; Aikichi Iwamoto; Michiyuki Matsuda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

10.  ADP-Ribosylation factor 1 (ARF1) regulates recruitment of the AP-3 adaptor complex to membranes.

Authors:  C E Ooi; E C Dell'Angelica; J S Bonifacino
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539

View more
  24 in total

1.  A diacidic motif in human immunodeficiency virus type 1 Nef is a novel determinant of binding to AP-2.

Authors:  O Wolf Lindwasser; William J Smith; Rittik Chaudhuri; Peter Yang; James H Hurley; Juan S Bonifacino
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

2.  The gamma/sigma1 and alpha/sigma2 hemicomplexes of clathrin adaptors AP-1 and AP-2 harbor the dileucine recognition site.

Authors:  Balraj Doray; Intaek Lee; Jane Knisely; Guojun Bu; Stuart Kornfeld
Journal:  Mol Biol Cell       Date:  2007-03-14       Impact factor: 4.138

3.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

4.  Down-modulation of CD8αβ is a fundamental activity of primate lentiviral Nef proteins.

Authors:  Anke Heigele; Michael Schindler; Clement W Gnanadurai; Jolie A Leonard; Kathleen L Collins; Frank Kirchhoff
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

5.  The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex.

Authors:  Yoshiko Usami; Sergei Popov; Heinrich G Göttlinger
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

6.  A Novel HIV-1 Nef Mutation in a Primary Pediatric Isolate Impairs MHC-Class I Downregulation and Cytopathicity.

Authors:  Ayub Ali; Robert L Furler; Livia Pedroza-Martins; Arnaud D Colantonio; Deborah Anisman-Posner; Yvonne Bryson; Otto O Yang; Christel H Uittenbogaart
Journal:  AIDS Res Hum Retroviruses       Date:  2019-11-04       Impact factor: 2.205

7.  Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor.

Authors:  Rittik Chaudhuri; O Wolf Lindwasser; William J Smith; James H Hurley; Juan S Bonifacino
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

8.  HIV-1 Nef binds PACS-2 to assemble a multikinase cascade that triggers major histocompatibility complex class I (MHC-I) down-regulation: analysis using short interfering RNA and knock-out mice.

Authors:  Katelyn M Atkins; Laurel Thomas; Robert T Youker; Melanie J Harriff; Franco Pissani; Huihong You; Gary Thomas
Journal:  J Biol Chem       Date:  2008-02-22       Impact factor: 5.157

9.  Competition model for upregulation of the major histocompatibility complex class II-associated invariant chain by human immunodeficiency virus type 1 Nef.

Authors:  Richard S Mitchell; Rittik Chaudhuri; O Wolf Lindwasser; Kristie A Tanaka; David Lau; Rudy Murillo; Juan S Bonifacino; John C Guatelli
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

10.  Prediction of HIV-1 virus-host protein interactions using virus and host sequence motifs.

Authors:  Perry Evans; William Dampier; Lyle Ungar; Aydin Tozeren
Journal:  BMC Med Genomics       Date:  2009-05-18       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.